欧洲肺动脉高压市场预测至 2028 年 - COVID-19 影响和药物区域分析 [内皮素受体拮抗剂 (ERA)、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 试纸]、类型（品牌和仿制药）、途径给药（口服、静脉/皮下和吸入）和分销渠道（医院药房和诊所、网上药房和零售药房）
No. of Pages: 148 | Report Code: BMIRE00028023 | Category: Life Sciences
No. of Pages: 148 | Report Code: BMIRE00028023 | Category: Life Sciences
肺动脉高血压发病率不断上升推动欧洲肺动脉高血压市场< /strong>
肺动脉高压（PAH）会影响肺部的微小动脉，使其变粗变窄，并阻塞流经肺部的血液。结果，肺部血压升高，心脏通过狭窄的动脉泵血时遇到困难。随着时间的推移，一个人的心脏会失去有效地将血液泵送到全身的能力。 PAH 通常影响 30 岁至 60 岁之间的女性。此外，根据 2019 年《欧洲呼吸评论》发表的一篇文章，苏格兰 PAH 的发病率为每百万人 7.6 例。存在家族史或已确定危险因素的特发性 PAH 甚至更为罕见，在苏格兰每百万人中就有 2.6 例。因此，肺动脉高压发病率的不断上升正在推动欧洲肺动脉高压市场的增长。
欧洲肺动脉高压高血压市场概述
欧洲肺动脉高压市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。该地区在全球肺动脉高压市场中占有重要的市场份额。由于产品批准量的增加，预计欧洲肺动脉高压市场在预测期内将出现显着增长。肺动脉高压是一种罕见疾病，在英国大约有两万人中就有一人患有肺动脉高压。 2021 年，英国有 7,876 人患有肺动脉高压。在英国，患有特发性肺动脉高压 (IPAH) 的年轻患者的 5 年生存率超过 80%。在英国，患有 PAH 和 CTEPH（该疾病是由肺血管系统变化的直接后果引起）的患者最常在全国九个专科中心接受治疗。英国肺动脉高压协会 (PHA-UK) 专门为肺动脉高压患者提供支持。因此，此类举措预计将在预测期内推动该国肺动脉高压药物市场的发展。
欧洲肺动脉高压动脉高血压市场细分
欧洲肺动脉高血压市场根据药物、类型、给药途径进行细分、分销渠道和国家。
根据药物，欧洲肺动脉高压市场分为内皮素受体拮抗剂（ERA）、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 试纸。 2022 年，前列环素和前列环素类似物细分市场在欧洲肺动脉高压市场中占据最大份额。
根据类型，欧洲肺动脉高压市场分为品牌药和仿制药。 2022年，品牌细分市场在欧洲肺动脉高压市场占据更大份额。
根据给药途径，欧洲肺动脉高压市场动脉高血压市场分为口服、静脉/皮下和吸入。 2022年，口服肺动脉高压市场份额最大。
从分销渠道来看，欧洲肺动脉高压市场高血压市场分为医院药房和诊所、网上药房和零售药房。 2022年，医院药房和诊所部门在欧洲肺动脉高压市场中占据最大份额。
按国家划分，欧洲肺动脉高压市场分为英国、德国、法国、意大利、西班牙和欧洲其他国家。 2022年，英国在欧洲肺动脉高压市场占据最大份额。
拜耳公司、吉利德科学公司、葛兰素史克公司、强生公司Johnson、Lupin Ltd、Novartis AG、Pfizer Inc、Teva Pharmaceutical Industries Ltd 和 United Therapeutics Corp 是欧洲肺动脉高压市场的领先公司。
Strategic insights for Europe Pulmonary Arterial Hypertension involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,959.47 Million |
| Market Size by 2028 | US$ 2,683.07 Million |
| Global CAGR (2022 - 2028) | 5.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 药物
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Pulmonary Arterial Hypertension refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Pulmonary Arterial Hypertension Market is valued at US$ 1,959.47 Million in 2022, it is projected to reach US$ 2,683.07 Million by 2028.
As per our report Europe Pulmonary Arterial Hypertension Market, the market size is valued at US$ 1,959.47 Million in 2022, projecting it to reach US$ 2,683.07 Million by 2028. This translates to a CAGR of approximately 5.4% during the forecast period.
The Europe Pulmonary Arterial Hypertension Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Pulmonary Arterial Hypertension Market report:
The Europe Pulmonary Arterial Hypertension Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Pulmonary Arterial Hypertension Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Pulmonary Arterial Hypertension Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Pulmonary Arterial Hypertension Market
